CN¥34.88
2.52%
Shanghai, Sep 24, 03:00 pm CST.
ISIN
CNE100003FF7
Symbol
688180

Shanghai Junshi Bioscience-h Stock price

CN¥34.88
+0.03 0.09% 1M
+1.67 5.03% 6M
+0.72 2.11% YTD
-6.79 16.29% 1Y
-3.10 8.16% 3Y
-21.19 37.79% 5Y
-116.12 76.90% 10Y
-116.12 76.90% 20Y
Shanghai, Closing price Thu, Sep 24 2026
-0.90 2.52%
ISIN
CNE100003FF7
Symbol
688180
Industry

Is Shanghai Junshi Bioscience-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
CN¥30.7b
Enterprise Value
CN¥33.0b
Net debt
CN¥2.2b
Cash
CN¥3.7b
Shares outstanding
1.0b
Valuation (TTM | estimate)
P/E
negative
P/S
10.2 | 9.1
EV/Sales
10.9 | 9.8
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
48.7%
Return on Equity
-14.5%
ROCE
-4.9%
ROIC
-6.1%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
CN¥3.0b | CN¥3.4b
EBITDA
-
EBIT
CN¥-555.4m
Net Income
CN¥-440.8m
Free Cash Flow
CN¥-1.1b
Growth (TTM | estimate)
Revenue
29.9% | 35.2%
EBITDA
-
EBIT
51.4%
Net Income
58.0%
Free Cash Flow
30.3%
Margin
Gross
82.0%
EBITDA
-
EBIT
-18.4%
Net
-14.6%
Free Cash Flow
-34.7%
More
EPS
CN¥-0.4
FCF per Share
CN¥-1.0
Short interest
-
Employees
3k
Rev per Employee
CN¥860.0k

Shanghai Junshi Bioscience-h Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Shanghai Junshi Bioscience-h forecast:

5x Buy
71%
1x Hold
14%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Shanghai Junshi Bioscience-h forecast:

Buy
71%
Hold
14%
Sell
14%

Financial data from Shanghai Junshi Bioscience-h

Jun '26
+/-
%
3,026 3,026
30% 30%
100%
- Direct Costs 545 545
19% 19%
18%
2,482 2,482
32% 32%
82%
- Selling and Administrative Expenses 1,638 1,638
8% 8%
54%
- Research and Development Expense 1,280 1,280
11% 11%
42%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -555 -555
51% 51%
-18%
Net Profit -441 -441
58% 58%
-15%

In millions CNY.

Don't miss a Thing! We will send you all news about Shanghai Junshi Bioscience-h directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 2,903 full-time employees. The company went IPO on 2018-12-24. Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The firm primarily operates its businesses in the domestic and American markets.

Head office China
CEO Ms. Zou
Employees 2,903
Website www.junshipharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today